drugset / Trial / NCT05692934

A HR20031 FE Study on Healthy Subjects

NCT05692934

Phase 1 Completed 40 enrolled Shandong Suncadia Medicine Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess the effect of food on the single-dose PK of SHR3824, SP2086 and metformin in the HR20031 FDC tablets in healthy subjects.

Timeline

Start
2023-01-31
Primary completion
2023-03-11
Completion
2023-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Henagliflozin Small molecule 10 mg
Subject Metformin Small molecule 1000 mg
Subject Metformin Small molecule 1500 mg
Subject Retagliptin Small molecule 100 mg